In 2018, advances in the treatment of non-small-cell lung cancer (NSCLC) have been observed both in trials of immunotherapies and targeted agents, leading to dramatically improved options for patients with metastatic and stage III NSCLC.
Patients with unresectable stage III NSCLC can benefit from consolidation therapy with durvalumab following chemoradiation11.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Herbst, R. S. et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387, 1540–1550 (2016).
Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
Gandhi, L. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N. Engl. J. Med. 378, 2078–2092 (2018).
Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1810865 (2018).
Jotte, R. M. et al. IMpower131: primary PFS and safety analysis of a randomized phase III study of atezolizumab + carboplatin + paclitaxel or nab-paclitaxel versus carboplatin + nab-paclitaxel as 1L therapy in advanced squamous NSCLC [abstract]. J. Clin. Oncol. 36 (Suppl. 18), LBA9000 (2018).
Mok, T. S. et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N. Engl. J. Med. 376, 629–640 (2017).
Soria, J. C. et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med. 378, 113–125 (2018).
Camidge, D. R. et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1810171 (2018).
Antonia, S. J. et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N. Engl. J. Med. 377, 1919–1929 (2017).
Antonia, S. J. et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1809697 (2018).
S.S.R. has served as a consultant for Abbvie, Amgen, AstraZeneca, Bristol Myers Squibb, Celgene, Lilly Oncology, Loxo, Merck, Nektar, Roche and Tesaro; has received travel support to attend advisory board meetings from AstraZeneca, EMD Serono and Pfizer; and his institution receives research support from Abbvie, AstraZeneca, Bristol Myers Squib, EMB Serono, Pfizer, Takeda and Vertex. J.W.C. declares no competing interests.
About this article
Cite this article
Carlisle, J.W., Ramalingam, S.S. A banner year for immunotherapy and targeted therapy. Nat Rev Clin Oncol 16, 79–80 (2019). https://doi.org/10.1038/s41571-018-0138-4
Nature Reviews Clinical Oncology (2021)
Large cell neuroendocrine lung carcinoma: consensus statement from The British Thoracic Oncology Group and the Association of Pulmonary Pathologists
British Journal of Cancer (2021)
British Journal of Cancer (2019)